跳至主要内容
临床试验/NL-OMON29980
NL-OMON29980尚未招募2 期

Preoperative short-term radiotherapy for primary resectable rectal cancer: Accelerated once daily (5x5Gy) versus accelerated hyperfractionated twice daily (12x2,5Gy b.i.d.) (ONCE-TWICE trial) A phase II single-blinded multi-institutional randomised study - ONCE-TWICE trial

niversitair Medisch Centrum Groningen0 个研究点目标入组 210 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
入组人数
210

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Primary resectable rectal cancer. All patients with primary resectable rectal cancer are eligible for the study, regardless whether a low anterior resection with primary anastomosis or an abdominoperineal resection is planned.
  • - Histologically proven adenocarcinoma
  • - No distant metastases
  • - No prior radiotherapy to the pelvis or abdomen
  • - Age >18 years
  • - WHO performance score 0-2
  • - Patients at reproductive age must agree to practice an effective contraceptive method
  • - Written informed consent

排除标准

  • - Non-resectable rectal cancer (or resectability uncertain)
  • - Histology other than adenocarcinoma
  • - Distant metastases
  • - Pregnancy or lactation
  • - Psychological, familial, sociological or geographical reasons hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

研究者

相似试验